23 Dec 2019 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO, James McBrayer talks about the company's joint venture to expand Positron Emission Tomography (PET) diagnostics business opportunities for NSW and Australia.
19 Dec 2019 - Renergen Limited (ASX:RLT) CEO Stefano Marani reveals the company's discovery of a 12% helium concentration reserve at the Virginia Gas Project in South Africa.
18 Dec 2019 - Oventus Medical Limited (ASX:OVN) Managing Director and CEO, Dr Chris Hart talks about the company's North American sales process via its lab in lab model and how this improves patient outcomes.
18 Dec 2019 - Prospect Resources Limited (ASX:PSC) Managing Director, Sam Hosack, provides an update on the company's Arcadia lithium project in Zimbabwe, including advanced negotiations with a number of African and international banks on funding.
17 Dec 2019 - Wisr Limited (ASX:WZR) CEO, Anthony Nantes talks about the company's partnership with NAB to provide an initial $50m in funding to support its personal loan book and diversify its funding partners.
17 Dec 2019 - Integrated Payment Technologies (ASX:IP1) CEO, Dean Martin discusses its payments solutions ClickSuper and PayVu, industry tailwinds, new features and platform integration.
17 Dec 2019 - Aus Tin Mining Limited (ASX:ANW) CEO, Peter Williams discusses the funding package and resumption plan for the Granville Tin Project and plans for Granville to be a foundation asset in a proposed IPO.
16 Dec 2019 - Sienna Cancer Diagnostics Limited (ASX:SDX) Managing Director and CEO Carl Stubbings talks about the company's capital raising and co-development of tests using its SIEN-NET liquid biopsies platform technology.
16 Dec 2019 - Openpay Group (ASX:OPY) CEO & MD, Michael Eidel talks about its business model, size of the opportunity and how it differentiates itself from other buy now pay later (BNPL) providers.
16 Dec 2019 - Botanix Pharmaceuticals Limited (ASX:BOT) Founder Matthew Callahan talks about the company's Phase 2 US trial results for severe acne, plans for its Phase 3 trails, including FDA input, its Phase 2 atopic dermatitis study, and what investors can expect over the next 6 months.
